Wei Zhang

Wei Zhang

Auto-generated profile, based on publicly available information

Wei Zhang

Department of Rheumatology and Immunology, First Hospital Affiliated to Baotou Medical College & Inner Mongolia Key Laboratory of Autoimmunity, Baotou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2022 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
WZWei Zhang
Wei Zhang
YWYong-Fu Wang
Yong-Fu Wang
FHFan-Lei Hu
Fan-Lei Hu
FLFu-Ai Lu
Fu-Ai Lu
TWTao Wu
Tao Wu
KLKe Li
Ke Li

3 January 2025 in Science Advances
Verified
Journal Article
Open access
YXYang Xie
Yang Xie
CWChaonan Wei
Chaonan Wei
DFDongdong Fu
Dongdong Fu
WZWei Zhang
Wei Zhang
YDYan Du
Yan Du
FHFanlei Hu
Fanlei Hu
Current diagnosis and treatment of rheumatoid arthritis (RA) is still challenging. More than one-third of patients with RA could not be accurately diagnosed because of lacking biomarkers. Our recent study reported that scavenger receptor-A (SR-A) is a biomarker for RA, especially for anticyclic citrullinated peptide antibody (anti-CCP)–negative RA. Here, we further identified the B cell autoantigenic epitopes of SR-A. By a large-scale multicenter study including one training and three validation cohorts of 1954 participants, we showed that anticitrullinated SR-A peptide antibody (anti-CSP) was exclusively elevated in RA as a biomarker, particularly useful for seronegative RA. Combination of anti-CSP with anti-CCP demonstrated superior diagnostic value for RA, with sensitivity of 84.83% and specificity of 92.43%. Moreover, RA anti-CSP revealed distinct glycosylation patterns, capable of provoking inflammation in cartilage organoids and exacerbating disease progression in experimental arthritis. Together, these data identify anti-CSP as an RA autoantibody clinically applicable and actively involved in disease pathogenesis.